Shop by goal

  • Metabolic Research
  • GH-Axis Research
  • Muscle & IGF Research
  • Tissue and Cellular Models
  • Regenerative Research
  • Cellular Senescence Research
  • Cognitive Research
  • Multi-Compound Blends
  • Accessories
  • All compounds →

    • Popular compounds

  • BPC-157
  • TB-500
  • GHK-Cu Copper Peptide
  • Retatrutide
  • Semaglutide
  • Ipamorelin
  • All bestsellers →

    • Research resources

  • Research Glossary
  • Peptide Guides
  • Delivery Guide
  • Track Order

    • Recently viewed

  • Peptide 101
  • Research Areas
  • Peptide Blog
  • Community Forum
  • Crypto Blog
  • Research Glossary
  • Reconstitution Calculator
  • Peptide Tracker
  • Research Protocol Tools
  • Peptide Guides
  • Sign In
  • Create Account
  • Track My Order
  • Refer a Friend
  • My Account
  • My Orders
  • My Referrals
  • Log Out
    • How-to guides

    RFK Jr. and FDA Peptide Regulations 2026: What Has Actually Changed?

    Short answer: On 20 October 2026, US Health Secretary Robert F. Kennedy Jr. said the administration wants a regulated market for certain peptides. Days earlier, an FDA interim peptide access policy had been received for White House review. That does not make BPC-157, TB-500 or any other investigational peptide FDA-approved. The policy is still under review, its text is unpublished, and the questions that matter — which substances, which pharmacies, for how long — are unanswered. The official regulatory record lists it (RIN 0910-ZD94) as received on 14 October.

    The latest status — 21 October 2026

    The FDA’s interim peptide policy is under White House review. A regulated market is being discussed, but the submission itself is not approval of investigational peptides.

    Source: US regulatory review record (reginfo.gov), RIN 0910-ZD94.

    What changed, and what hasn’t?

    What changed

    The administration has said publicly that it wants a regulated peptide marketplace, and an FDA interim access policy for compounding certain peptides is now under White House review.

    What hasn’t

    No peptide has been approved by the FDA. The policy text is unpublished, no list of covered substances is confirmed, no start date is set, and a permanent change would still need rulemaking.

    What did RFK Jr. announce about peptides?

    Speaking on Fox News’ The Will Cain Show on 20 October, Kennedy was asked about the pending FDA policy. According to Reuters, he made three points:

    The goal “A regulated marketplace, so that what they’re getting is what they claim to be.”
    Oversight Products should be safe and “the factories are inspected.”
    Demand “Americans are going to be buying these anyway.”

    The same report notes that Kennedy acknowledged the peptides under consideration have not been approved by the FDA as safe or effective . His argument is about where products come from and how they are made. It is not a claim that the compounds work.

    What is the FDA interim peptide access policy?

    The federal review tracker lists an FDA submission titled Interim Access Policy for Compounding Using Certain Peptides . Its text has not been published, so nobody outside government can yet say which peptides it names or what conditions it sets.

    Document Interim Access Policy for Compounding Using Certain Peptides Agency HHS – Food and Drug Administration Regulation identifier RIN 0910-ZD94 Received for review 14 October 2026, Office of Information and Regulatory Affairs (OIRA) Stage and status Notice · pending review Published text None yet Reported mechanism FDA enforcement discretion for pharmacy compounding of certain peptides (Associated Press, citing two people familiar with the plan) Covered substances Not confirmed Effective date Not set

    Status checked 21 October 2026 against reginfo.gov, the federal regulatory review tracker.

    What does “enforcement discretion” mean?

    It means the agency says it will not act against a defined activity, under defined conditions, even though the underlying rule has not changed. The Associated Press (via STAT), citing two people familiar with the plan, reports that the policy would let pharmacies temporarily compound some popular peptides, including BPC-157. Enforcement discretion can be issued faster than a regulation and withdrawn just as fast, which is why it is called interim .

    Interim policy, permanent rule or FDA approval?

    Pathway What it does How it happens Interim enforcement discretion The FDA declines to act against certain pharmacy compounding of named substances, for a time Agency policy; can be issued and withdrawn relatively quickly 503A bulks list inclusion Lets licensed pharmacies compound a substance under the 503A framework on a lasting basis Notice-and-comment rulemaking, which reporting says could take years FDA drug approval Establishes that a specific product is safe and effective for a specific use Clinical trials, manufacturing review and a formal application

    The pending policy sits in the first row only. Compounded drugs are not FDA-approved products, even when compounding is lawful.

    Are peptides legal in the US in 2026?

    There is no single answer, and no blanket legalisation has been announced. It depends on the product and what it is sold for:

  • FDA-approved peptide medicines have completed the drug approval process for specified uses (how FDA approval works).
  • Compounded medicines may be prepared by pharmacies under defined legal conditions, but compounded drugs are not themselves FDA-approved. This is the category the interim policy concerns.
  • Research-use-only compounds are laboratory materials supplied for scientific and analytical work, not as medicines and not for human or veterinary use.

    • Was the peptide ban lifted? Not yet. In 2023 the FDA placed BPC-157 and other peptides among the substances it said may present significant safety risks in compounding (the 2023 decision). The July 2026 advisory vote was non-binding, and as of 21 October no published FDA action has lifted those restrictions. For the wider US, UK and EU position, see are peptides legal?

    Which peptides are being reviewed by the FDA?

    Seven substances went before the FDA’s Pharmacy Compounding Advisory Committee on 23–24 July 2026. Whether the interim policy covers any of them has not been confirmed ; the published listing does not name covered substances.

    Substance July 2026 advisory vote Final FDA decision Covered by interim policy FDA-approved drug BPC-157 8–6 Recommended Not yet Unconfirmed No KPV 8–6 Recommended Not yet Unconfirmed No TB-500 8–6 Recommended Not yet Unconfirmed No MOTS-c 7–5 Recommended Not yet Unconfirmed No Semax 8–5 Recommended Not yet Unconfirmed No Epitalon 7–5 Recommended Not yet Unconfirmed No Emideltide (DSIP) 6–7 Not recommended Not yet Unconfirmed No

    Vote tallies as reported by Arent Fox Schiff. FDA staff recommended against all seven. An advisory vote does not bind the FDA.

    Four things that are not interchangeable

  • Advisory committee recommendation: outside experts advise the FDA. It is non-binding.
  • Reviewed for compounding: a substance considered for the 503A bulks list. Being reviewed is not the same as being listed.
  • Final FDA decision: the agency’s own action. For the permanent list, that means notice-and-comment rulemaking.
  • Formal approval of a medicine: a drug application backed by clinical evidence and manufacturing review. None of the seven has this.

    • How we got here: a sourced timeline

    Where the policy stands: the July advisory votes, White House review since 14 October, and the rulemaking a permanent change would need.
  • 2023: the FDA places BPC-157 and other peptides among the bulk substances it says may present significant safety risks in compounding (the 2023 decision).
  • Early 2026: according to the AP, Kennedy directs the FDA to reconsider a short list of widely promoted peptides (background and terminology).
  • 23–24 July 2026: the advisory committee recommends six of seven substances, against FDA staff advice (the full vote report).
  • 14 October 2026: the interim access policy is received for White House review.
  • 20 October 2026: Kennedy describes the goal as a regulated peptide marketplace.

    • BPC-157, TB-500, KPV and MOTS-c: what we know

    A short status for four of the seven. None is an FDA-approved medicine, and nothing here is a claim about what any of them does.

    BPC-157

    A synthetic peptide studied in laboratory and animal research.

  • July vote: 8–6, recommended
  • FDA-approved drug: no
  • Interim policy coverage: not confirmed

    • Is BPC-157 FDA-approved? · Research guide

    TB-500

    A synthetic peptide related to thymosin beta-4, used in laboratory research.

  • July vote: 8–6, recommended
  • FDA-approved drug: no
  • Interim policy coverage: not confirmed

    • Is TB-500 FDA-approved? · Research guide

    KPV

    A short peptide fragment related to alpha-MSH, studied in cell and animal models.

  • July vote: 8–6, recommended
  • FDA-approved drug: no
  • Interim policy coverage: not confirmed

    • KPV and the FDA review · Research guide

    MOTS-c

    A peptide encoded in mitochondrial DNA, studied in metabolic research.

  • July vote: 7–5, recommended
  • FDA-approved drug: no
  • Interim policy coverage: not confirmed

    • July vote report · Research guide

    Does this affect research-use-only peptides?

    Not directly, as far as anything published shows. The reported policy concerns pharmacy compounding of certain peptides. It does not mention research-use-only (RUO) supply to laboratories. What it does is raise the stakes on questions every research supplier should already be able to answer: what is in the vial, who tested it, and what is the product sold for?

    Pharmacy compounding vs. research-use-only supply

    Question Pharmacy compounding (what the policy concerns) Research-use-only supply Who is it for? Individual patients, on a prescription Laboratories and independent researchers Intended use Human use, under a prescriber Laboratory and analytical work only; not for human or veterinary use Who sets the rules? FDA compounding rules and state pharmacy regulators Labelling, marketing-claim and import rules, which differ by country What shows quality? Pharmacy standards and inspection Independent analytical testing and published Certificates of Analysis Affected by the interim policy? Yes: this is the activity it concerns, as reported Not directly, as far as published; scope still unknown

    General information, not legal advice. Rules differ by country.

    What it means for online suppliers and independent researchers

  • Documentation becomes the differentiator. A debate about a regulated market is a debate about identity and purity. Suppliers that name the testing laboratory, publish the result and say what a certificate does and does not show are better placed than those that do not.
  • Marketing claims draw scrutiny. Arent Fox Schiff notes that the FDA’s enforcement focus on peptide marketing claims remains active, whatever the advisory vote. For a supplier, that means no dosing, treatment or human-outcome claims, and no suggestion that research materials are medicines.
  • Cross-border supply stays a local-law question. This is a US compounding matter. Researchers ordering from outside the US remain subject to their own country’s import and research-chemical rules, and delivery terms will keep varying by destination.
  • A regulated pharmacy channel, if it arrives, serves a different need. It would concern prescribed medicines for patients. Research materials stay defined by intended use: analytical and laboratory research.

    • How New-U approaches this

    New-U Research Compounds supplies peptides for laboratory research use only, to independent researchers, with delivery worldwide. Delivery charges vary by destination and are shown at checkout before payment; see delivery. Every released sale batch must pass independent verification before it is offered for sale, and Certificates of Analysis from independent laboratories, Janoshik Analytical and Freedom Diagnostics, are published on the website at /coa where a report exists.

    A certificate reports what one laboratory measured in one submitted sample on the test date shown on the report. The public record does not state which sale lot that sample came from, so a certificate shows the measured result for the sample analysed, not the composition of a particular vial or order. It is not evidence of safety or effectiveness in people. New-U will keep tracking the FDA’s review and update this article when the policy text is published.

    How to evaluate any research supplier

  • Is the testing laboratory named, and independent of the seller?
  • Can you read the certificate before you buy? See how to read a certificate of analysis.
  • Does the supplier say what a certificate cannot show? See what a peptide COA cannot tell you.
  • Is every product labelled research use only, with no dosing or treatment claims?
  • Are delivery terms and charges clear for your country?
  • Can you ask the supplier about a specific compound? More in how to choose a peptide supplier and our page on lab-tested research compounds.

    • What happens next?

    What to watch

  • OIRA clearance: whether the White House concludes its review, and when.
  • Publication: the text itself, meaning which peptides, which pharmacies and which conditions.
  • Duration: whether the interim policy has an end date or is tied to rulemaking.
  • Rulemaking: whether the FDA proposes adding substances to the 503A bulks list, which would open a public comment period.
  • Legal challenges: whether the policy is contested, as the 2023 decision was.

    • Where the debate stands

  • Supporters argue that demand already exists and that moving supply into inspected pharmacies improves identity and quality control.
  • Critics point to FDA staff scientists who, according to the AP, said none of the seven peptides had been studied enough to establish safety and effectiveness. Enforcement discretion, they note, postpones the evidence question rather than answering it. See also our report on the unregulated peptide grey market.

    • We will update this article when the policy is published.

    Frequently asked questions

    What did RFK Jr. say about peptides in October 2026? On 20 October 2026, in an interview on Fox News, HHS Secretary Robert F. Kennedy Jr. said the administration wants a regulated marketplace for peptides, so that what people get is what it claims to be and the factories are inspected. He also acknowledged, as Reuters reported, that the peptides under consideration have not been approved by the FDA as safe or effective.

    What is the FDA's Interim Access Policy for Compounding Using Certain Peptides? It is an FDA document (RIN 0910-ZD94) received by the White House Office of Information and Regulatory Affairs on 14 October 2026 and listed as pending review. Its text has not been published. According to the Associated Press, it would let the FDA use enforcement discretion so that pharmacies could temporarily compound some popular peptides, including BPC-157.

    Are peptides legal in the US in 2026? Not in a blanket sense. FDA-approved peptide medicines are legal for their approved uses, compounded peptides are lawful only under defined conditions, and research-use-only materials are sold for laboratory work, not for human or veterinary use. The pending interim policy concerns pharmacy compounding. It is not FDA approval, and a permanent change to the compounding lists would still require notice-and-comment rulemaking.

    Is BPC-157 FDA-approved in 2026? No. BPC-157 was one of six peptides an FDA advisory committee voted to recommend for the 503A bulks list in July 2026, against the advice of FDA staff. That vote was non-binding, and neither it nor the pending interim policy is a drug approval.

    Which peptides does the interim access policy cover? That has not been confirmed. The policy text is unpublished, and the regulatory listing does not name covered substances. The FDA advisory committee reviewed seven in July 2026: BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon and Emideltide (DSIP). Reporting says the policy would let pharmacies temporarily compound some popular peptides, including BPC-157.

    When will the new peptide policy take effect? No date has been set. As of 21 October 2026 the policy is pending White House review. It would need to be finalised and published before anyone can know its scope, conditions or start date.

    Does the policy apply to research-use-only peptide suppliers? Nothing published so far says so. The reported scope is pharmacy compounding, which is prescription medicine prepared by licensed pharmacies. Research-use-only materials are supplied to laboratories and independent researchers and are not for human or veterinary use, so it would be premature to assume the policy changes their position either way.

    What does the FDA peptide policy mean for research peptide suppliers and independent researchers? Nothing changes automatically. The debate raises expectations around independent testing, published Certificates of Analysis, honest labelling and the absence of medical claims. Researchers outside the US remain subject to their own country's import and research-chemical rules.

    Does this change peptide rules in the UK or EU? No. The proposal concerns US oversight of compounding. UK and EU rules on medicines, research chemicals and imports are separate and are not changed by it.

    Related reading

  • FDA Panel Votes to Loosen Peptide Restrictions: the July 2026 scoreboard
  • Is BPC-157 FDA-approved? The 2026 regulatory status
  • Semax, Epitalon and DSIP: the July 24 session
  • Is the FDA changing its position on peptides?
  • FDA Peptide Reclassification 2026: what changed, and why
  • Pharmaceutical-grade vs research-grade peptides
  • How to read a certificate of analysis

    • Sources

  • reginfo.gov — HHS regulatory reviews pending at OIRA (primary record, RIN 0910-ZD94)
  • Reuters — Kennedy says Trump administration aims for regulated market for peptides (20 October 2026)
  • Associated Press via STAT — Trump administration advances plan for peptide drugs favored by RFK Jr. (15 October 2026)
  • Arent Fox Schiff — FDA panel recommends six of seven for compounding
  • FDA — July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting
  • FDA — Compounding and the FDA: Questions and Answers
  • FDA — Certain bulk drug substances that may present significant safety risks

    • Regulatory status checked 21 October 2026. This article is general industry information, not medical or legal advice. External links are provided for reference only; New-U is not affiliated with these organisations and links carry no endorsement either way.

    From the Lab - Peptides on LinkedIn & Facebook

    Certificates of Analysis, published online

    New-U Research Compounds supplies peptides for laboratory research. For laboratory and research use only — not for human or veterinary use. Where a report exists, Certificates of Analysis are published on the website, on the product page and at /coa.

    Research use only - all claims made on this site are for testing and research use only.

    PRECISION. PURITY. PERFORMANCE.

    Research peptides. Third-party Certificates of Analysis (Janoshik Analytical & Freedom Diagnostics) are published on the website. Supplied strictly for laboratory research use.

    Shop

  • All research compounds
  • Price list
  • Where to buy peptides
  • Compare compounds
  • Compare vial sizes
  • Affiliate programme

    • Research

  • Peptide 101
  • Published COAs
  • Research areas
  • Research blog
  • How-to guides
  • Peptide guides
  • Research glossary

    • Support

  • Track your order
  • Contact us
  • Shipping & delivery
  • International shipping
  • FAQ
  • Community forum
  • Refund policy

    • Ways to Pay

  • Google Pay
  • Apple Pay
  • Venmo
  • Cryptocurrency
  • Crypto wallets
  • Cash App
  • Card payments
  • Bank transfer (SEPA)
  • Paying with crypto
  • Live crypto prices

    • Shop by goal

  • Metabolic Research
  • GH-Axis Research
  • Muscle & IGF Research
  • Tissue and Cellular Models
  • Regenerative Research
  • Cellular Senescence Research
  • Cognitive Research
  • Multi-Compound Blends
  • Accessories

    • Shop by compound

  • BPC-157
  • TB-500
  • GHK-Cu
  • Tesamorelin
  • Retatrutide
  • Semaglutide
  • Tirzepatide
  • CJC-1295 (without DAC)
  • All compounds →
    • Shop by region
  • United Kingdom
  • United States
  • Australia
  • Canada
  • Canada (FR)
  • Ireland
  • Northern Ireland
  • Malta
  • Germany
  • France
  • Spain
  • Italy
  • Netherlands
  • Portugal
  • Greece
  • Austria
  • Poland
  • Sweden
  • Finland
  • Denmark
  • Norway
  • Croatia
  • Slovakia
  • Slovenia
  • Estonia
  • Latvia
  • Lithuania
  • Czechia
  • Hungary
  • Romania
  • Bulgaria
  • Belgium
  • Belgium (FR)
  • Luxembourg
  • Deutsch
  • Ελληνικά
  • Español
  • Français
  • Italiano

    • Research use only - all claims made on this site are for testing and research use only. Purchasers must be 21 years of age or older.

    All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.

    Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.

    Principal office: 1712 Pioneer Ave., Ste. 500, Cheyenne, WY 82001, USA

    © 2026 New-U Research Compounds · new-u.io

    [image: Peptide Regulation 2026: glass research vials and peptide molecule models in front of the US Capitol at dusk]

    [image: Timeline of US peptide regulation in 2026: the July advisory committee votes, the interim access policy received for White House review on 14 October, and possible rulemaking to come]

    [image: New-U Research Compounds on PepFinder, PepFinder rating 8.5 out of 10, store checked]

    Research use only — not for human consumption. All products are supplied strictly for laboratory research purposes.

    © 2026 New-U Research Compounds · new-u.io — Copyright held with Hilxera Distribution Services LLC. All rights reserved.